Biologic and targeted therapeutics in vitiligo.
Priyanka KaragaiahRobert A SchwartzTorello LottiUwe WollinaStephan GrabbeMohamad GoldustPublished in: Journal of cosmetic dermatology (2022)
JAK inhibitors have shown promising results and good tolerability; Adjuvant phototherapy can achieve a superior response compared to monotherapy. Though TNF-ꭤ has been tried in a few cases, it is best used if vitiligo is present in association with other chronic autoimmune diseases for which it is indicated. More in vitro studies and clinical research are required to understand the pathogenesis clearly, and therapy has to be targeted at specific pathways for a better approach toward vitiligo. Treatment aimed at induction and differentiation of melanocytes may be added to achieve faster repigmentation.